Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Ingraham, Charles H. IV ; Stalinska, Joanna ; Carson, Sean C. , et al. SCI REP-UK,2023,13(1):12236. DOI: 10.1038/s41598-023-39236-w PubMed ID: 37507404
More
Abstract: Glioblastomas are highly aggressive brain tumors for which therapeutic options are very limited. In a quest for new anti-glioblastoma drugs, we focused on specific structural modifications to the benzoyl-phenoxy-acetamide (BPA) structure present in a common lipid-lowering drug, fenofibrate, and in our first prototype glioblastoma drug, PP1. Here, we propose extensive computational analyses to improve the selection of the most effective glioblastoma drug candidates. Initially, over 100 structural BPA variations were analyzed and their physicochemical properties, such as water solubility (- logS), calculated partition coefficient (ClogP), probability for BBB crossing (BBB_SCORE), probability for CNS penetration (CNS-MPO) and calculated cardiotoxicity (hERG), were evaluated. This integrated approach allowed us to select pyridine variants of BPA that show improved BBB penetration, water solubility, and low cardiotoxicity. Herein the top 24 compounds were synthesized and analyzed in cell culture. Six of them demonstrated glioblastoma toxicity with IC50 ranging from 0.59 to 3.24 μM. Importantly, one of the compounds, HR68, accumulated in the brain tumor tissue at 3.7 ± 0.5 μM, which exceeds its glioblastoma IC50 (1.17 μM) by over threefold.
Purchased from AmBeed: 20173-04-0 ; 1539-42-0 ; 16867-03-1 ; 85622-93-1 ; 13207-66-4 ; 591-54-8 ; 6971-44-4 ; 18364-47-1 ; 45695-03-2 ; 2706-56-1 ; 21035-59-6 ; 90-45-9 ; 40154-75-4 ; 38767-72-5 ; 33630-99-8 ; 3731-52-0 ; 27854-90-6 ; 20173-24-4 ; 3731-53-1 ; 42017-89-0 ; 13010-47-4 ; 154-93-8 ; 3731-51-9 ; 56129-55-6 ; 671-16-9 ; 42017-89-0 ; 90-45-9 ...More
CAS No. : | 85622-93-1 | MDL No. : | MFCD00866492 |
Formula : | C6H6N6O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | BPEGJWRSRHCHSN-UHFFFAOYSA-N |
M.W : | 194.15 | Pubchem ID : | 5394 |
Synonyms : |
NSC 362856;CCRG 81045;Temodar. Foreign brand name: Temodal;TMZ. US brand names: Methazolastone;RP46161;SCH-52365;Temodal;Methazolastone;MB 39831;TMZ
|
Chemical Name : | 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide |
Signal Word: | Danger | Class: | 9 |
Precautionary Statements: | P201-P202-P261-P264-P270-P271-P273-P280-P301+P312+P330-P302+P352-P304+P340+P312-P305+P351+P338-P308+P313-P332+P313-P337+P313-P403+P233-P405-P501 | UN#: | 3077 |
Hazard Statements: | H302-H315-H319-H335-H340-H350-H401-H411 | Packing Group: | Ⅲ |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.